TNFRSF11A

Chr 18ADAR

TNF receptor superfamily member 11a

Also known as: CD265, FEO, LOH18CR1, ODFR, OFE, OPTB7, OSTS, PDB2

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptors can interact with various TRAF family proteins, through which this receptor induces the activation of NF-kappa B and MAPK8/JNK. This receptor and its ligand are important regulators of the interaction between T cells and dendritic cells. This receptor is also an essential mediator for osteoclast and lymph node development. Mutations at this locus have been associated with familial expansile osteolysis, autosomal recessive osteopetrosis, and Paget disease of bone. Alternatively spliced transcript variants have been described for this locus. [provided by RefSeq, Aug 2012]

OMIMResearchGenerating clinical summary…
MultiplemechanismAD/ARLOEUF 0.603 OMIM phenotypes
Clinical SummaryTNFRSF11A
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.33) despite low pLI — interpret in context.
📋
ClinVar Variants
35 unique Pathogenic / Likely Pathogenic· 453 VUS of 796 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.60LOEUF
pLI 0.009
Z-score 3.05
OE 0.33 (0.190.60)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.29Z-score
OE missense 0.81 (0.730.89)
279 obs / 346.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.33 (0.190.60)
00.351.4
Missense OE?0.81 (0.730.89)
00.61.4
Synonymous OE?0.85
01.21.6
LoF obs/exp: 8 / 24.2Missense obs/exp: 279 / 346.5Syn Z: 1.42

This gene — mechanism propensity

DN
0.76top 25%
GOF
0.81top 10%
LOF
0.3065th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 1 literature citation
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFOur findings: i) reveal that JPD can be associated with an activating mutation within TNFRSF11A, ii) expand the range and overlap of phenotypes among the Mendelian disorders of RANK activation, and iii) call for mutation analysis to improve diagnosis, prognostication, recurrence risk assessment, and1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 25063546

ClinVar Variant Classifications

796 submitted variants in ClinVar

Classification Summary

Pathogenic23
Likely Pathogenic12
VUS453
Likely Benign225
Benign42
Conflicting29
23
Pathogenic
12
Likely Pathogenic
453
VUS
225
Likely Benign
42
Benign
29
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
15
6
2
0
23
Likely Pathogenic
7
5
0
0
12
VUS
11
377
59
6
453
Likely Benign
1
11
71
142
225
Benign
0
2
36
4
42
Conflicting
29
Total34401168152784

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

89 pathogenic / likely-pathogenic (of 93) ClinVar copy-number / structural variants overlap TNFRSF11A — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

TNFRSF11A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →